IL6 and neuromyelitis optica: Excitingly, there are many emerging therapies currently under investigation including monoclonal antibodies directed toward elements of the complement cascade, IL-6, CD19+ plasma cells, and AQP4 itself, as well as therapeutics targeting granulocytes involved in inflammation in NMO and complement inhibitors.